NXI Therapeutics raises CHF 3.5 million in Pre-Seed financing to innovate novel immunotherapies
NXI Therapeutics, a Biozentrum University of Basel spin-off focused on innovative immunotherapies, has extended its pre-seed financing to CHF 3.5 million. This funding will accelerate the development of revolutionary immunotherapies by modulating coronin 1 in immune cells, positioning the company at the forefront of next-generation treatments.
NXI Therapeutics, known for developing innovative immunotherapies through coronin 1 modulation, has announced a pre-Seed financing extension of 3.5 million CHF. This precedes a larger Seed financing round currently in progress.New investor Kickfund joins existing investors such as JFG Life Sciences Foundation, BaseLaunch, and Venture Kick. The company has also received support from an InnoBooster grant from the Gebert Rüf Foundation and a Propelling grant from the University of Basel. Additionally, Patrick Burgermeister, CEO of JFG Life Sciences Foundation, will join NXI’s Board of Directors. He brings extensive experience from roles in venture capital, pharma, and banking, and holds a Master’s degree in Molecular Biology.
NXI Therapeutics was ranked among the TOP 100 Swiss Startups, won the final stage of Venture Kick in 2022, and participated in Venture Leaders Biotech in 2021.
"The Boston Venture Leaders road show was a great opportunity to learn about best practices in the Boston Biotech ecosystem. We were also introduced to several US investors that could potentially invest in our company," highlighted Rajesh Jayachandran, Co-Founder and CSO of NXI Therapeutics.
NXI Therapeutics Co-Founders: CEO Ruben Herrendorff and CSO Rajesh Jayachandran
NXI Therapeutics AG: NXI Therapeutics creates tomorrow's safe immunotherapies.
NXI Therapeutics is a spin-off from the Biozentrum, University of Basel, and is committed to creating tomorrow's safe immunotherapies for immunodermatological diseases with unmet needs. NXI is pioneer... Read more
